ADVERTENT BIOTHERAPEUTICS, INC.

East Lansing, MI · Biotech · Private

ADA011, a TGF-β1/3 inhibitor small molecule therapeutic for muscular dystrophy

advertentbio.com →
Grants
$1.5M
2 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · A novel agent for preventing fatty degeneration of muscles in LGMD2B$250,011
Federal grantDepartment of Health and Human Services · Phase II · A novel agent for preventing fatty degeneration of muscles in LGMD2B$1,292,847
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2191SILCSBIO LLC——
2192Hemab Therapeutics——
2193Medosome Biotec, LLC——
2194ADVERTENT BIOTHERAPEUTICS, INC.——
2195Avometric——
2196OVATION SCIENCE INC.—$150K
2197Conagen inc——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.